87 related articles for article (PubMed ID: 20596672)
21. Targeting FOXM1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer.
Westhoff GL; Chen Y; Teng NNH
Int J Gynecol Cancer; 2017 Oct; 27(8):1602-1609. PubMed ID: 28692634
[TBL] [Abstract][Full Text] [Related]
22. Role of human epididymis protein 4 in chemoresistance and prognosis of epithelial ovarian cancer.
Lee S; Choi S; Lee Y; Chung D; Hong S; Park N
J Obstet Gynaecol Res; 2017 Jan; 43(1):220-227. PubMed ID: 27862665
[TBL] [Abstract][Full Text] [Related]
23. CYP1B1 enhances the resistance of epithelial ovarian cancer cells to paclitaxel in vivo and in vitro.
Zhu Z; Mu Y; Qi C; Wang J; Xi G; Guo J; Mi R; Zhao F
Int J Mol Med; 2015 Feb; 35(2):340-8. PubMed ID: 25516145
[TBL] [Abstract][Full Text] [Related]
24. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
Laframboise S; Chapman W; McLaughlin J; Andrulis IL
Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
[TBL] [Abstract][Full Text] [Related]
25. Reversal of paclitaxel resistance in epithelial ovarian carcinoma cells by a MUC1 aptamer-let-7i chimera.
Liu N; Zhou C; Zhao J; Chen Y
Cancer Invest; 2012 Oct; 30(8):577-82. PubMed ID: 22812695
[TBL] [Abstract][Full Text] [Related]
26. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
George JA; Chen T; Taylor CC
Cancer Res; 2005 Nov; 65(22):10381-8. PubMed ID: 16288028
[TBL] [Abstract][Full Text] [Related]
27. Involvement of GRP78 in the Resistance of Ovarian Carcinoma Cells to Paclitaxel.
Zhang LY; Li PL; Xu A; Zhang XC
Asian Pac J Cancer Prev; 2015; 16(8):3517-22. PubMed ID: 25921171
[TBL] [Abstract][Full Text] [Related]
28. Weakened spindle checkpoint with reduced BubR1 expression in paclitaxel-resistant ovarian carcinoma cell line SKOV3-TR30.
Fu Y; Ye D; Chen H; Lu W; Ye F; Xie X
Gynecol Oncol; 2007 Apr; 105(1):66-73. PubMed ID: 17234259
[TBL] [Abstract][Full Text] [Related]
29. Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells.
Lee J; An S; Choi YM; Lee J; Ahn KJ; Lee JH; Kim TJ; An IS; Bae S
Int J Oncol; 2016 Nov; 49(5):1945-1952. PubMed ID: 27600258
[TBL] [Abstract][Full Text] [Related]
30. Metformin and epithelial ovarian cancer therapeutics.
Patel S; Kumar L; Singh N
Cell Oncol (Dordr); 2015 Oct; 38(5):365-75. PubMed ID: 26266765
[TBL] [Abstract][Full Text] [Related]
31. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells.
Kajiyama H; Shibata K; Terauchi M; Yamashita M; Ino K; Nawa A; Kikkawa F
Int J Oncol; 2007 Aug; 31(2):277-83. PubMed ID: 17611683
[TBL] [Abstract][Full Text] [Related]
32. TXNDC17 promotes paclitaxel resistance via inducing autophagy in ovarian cancer.
Zhang SF; Wang XY; Fu ZQ; Peng QH; Zhang JY; Ye F; Fu YF; Zhou CY; Lu WG; Cheng XD; Xie X
Autophagy; 2015; 11(2):225-38. PubMed ID: 25607466
[TBL] [Abstract][Full Text] [Related]
33. Proteomic analysis of human ovarian cancer paclitaxel-resistant cell lines.
Cao L; Li X; Zhang Y; Peng F; Yi H; Xu Y; Li X; Wang Q
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Apr; 35(4):286-94. PubMed ID: 20448348
[TBL] [Abstract][Full Text] [Related]
34. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
Sonnemann J; Gänge J; Pilz S; Stötzer C; Ohlinger R; Belau A; Lorenz G; Beck JF
BMC Cancer; 2006 Jul; 6():183. PubMed ID: 16834771
[TBL] [Abstract][Full Text] [Related]
35. Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma.
Bonneau C; Rouzier R; Geyl C; Cortez A; Castela M; Lis R; Daraï E; Touboul C
Gynecol Oncol; 2015 Jan; 136(1):112-20. PubMed ID: 25449309
[TBL] [Abstract][Full Text] [Related]
36. Quantitative proteomic analysis of mitochondria from human ovarian cancer cells and their paclitaxel-resistant sublines.
Chen M; Huang H; He H; Ying W; Liu X; Dai Z; Yin J; Mao N; Qian X; Pan L
Cancer Sci; 2015 Aug; 106(8):1075-83. PubMed ID: 26033570
[TBL] [Abstract][Full Text] [Related]
37. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
Tang X; Lu M; Li C; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of glycogen synthase kinase-3 in ovarian carcinoma cells with acquired paclitaxel resistance.
Fu Y; Hu D; Qiu J; Xie X; Ye F; Lu WG
Int J Gynecol Cancer; 2011 Apr; 21(3):439-44. PubMed ID: 21436692
[TBL] [Abstract][Full Text] [Related]
39. Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer.
Ryner L; Guan Y; Firestein R; Xiao Y; Choi Y; Rabe C; Lu S; Fuentes E; Huw LY; Lackner MR; Fu L; Amler LC; Bais C; Wang Y
Clin Cancer Res; 2015 Jul; 21(13):2941-51. PubMed ID: 25838397
[TBL] [Abstract][Full Text] [Related]
40. IGF-1R inhibition potentiates cytotoxic effects of chemotherapeutic agents in early stages of chemoresistant ovarian cancer cells.
Singh RK; Gaikwad SM; Jinager A; Chaudhury S; Maheshwari A; Ray P
Cancer Lett; 2014 Nov; 354(2):254-62. PubMed ID: 25157649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]